TheranosticTrials.org

Clinical Trial · NCT07023068

⁶⁸Ga-DPA in the Lung Cancer Diagnosis

Overview

In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Zhaohui Zhu (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07023068

Drug / Compound

DPA

Isotope(s):
Target(s):
  • PD-L1
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • Expected survival \>3 months.
  • At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Patients clinically confirmed or suspected of lung cancer, with pathological specimens obtainable via biopsy or surgery within the recent 2 months.

Exclusion

  • Severe hepatic or renal dysfunction (serum creatinine \>3.0 mg/dL or any liver enzyme level ≥5× upper limit of normal).
  • Other conditions deemed ineligible by the investigator.
  • Women who are planning pregnancy, pregnant, or breastfeeding.
  • Claustrophobia or other psychiatric disorders.
  • Intolerance to any clinical procedures in the study.
  • Inability to lie supine for 30 minutes.